Canaccord lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $11 from $12 and keeps a Buy rating on the shares. The firm believes TriSalus has the foundation of a strong medical device business with a commercial footprint and catalysts to support it including new product launches and clinical data.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio